Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. Mk-0616 (chloride)
2. R7ez772vg2
3. Gtpl13944
4. 2407527-14-2
5. L-proline, L-alanyl-3-[[1-oxo-6-(trimethylammonio)hexyl]amino]-d-alanyl-3-[[(2-hydroxyacetyl)amino]methyl]-l-phenylalanyl-1-[6-[[[4-(2-aminoethyl)phenyl]methyl](3-carboxy-1-oxopropyl)amino]hexyl]-5-fluoro-l-tryptophyl-(3s)-3-hydroxy-l-prolyl-l-threonyl-o-methyl-l-tyrosyl-2-methyl-, (4-->1),(8-->4)-dilactam, Cyclic (3-->5)-ether
| Molecular Weight | 1550.8 g/mol |
|---|---|
| Molecular Formula | C82H110FN14O15+ |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 12 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 366 |
| Heavy Atom Count | 112 |
| Formal Charge | 1 |
| Complexity | 3240 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Enlicitide is a peptide drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Lead Product(s): Enlicitide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2026
Lead Product(s) : Enlicitide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enlicitide is a peptide drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 19, 2026
Details:
Enlicitide is a peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Enlicitide,Rosuvastatin Calcium
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 23, 2025
Lead Product(s) : Enlicitide,Rosuvastatin Calcium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
Details : Enlicitide is a peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 23, 2025
Details:
Enlicitide is a Peptide, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hyperlipidemias.
Lead Product(s): Enlicitide,Rosuvastatin Calcium
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 14, 2025
Lead Product(s) : Enlicitide,Rosuvastatin Calcium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Details : Enlicitide is a Peptide, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hyperlipidemias.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 14, 2025
Details:
Enlicitide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Enlicitide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2025
Lead Product(s) : Enlicitide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Coffee & Tea on Enlicitide in Healthy Volunteers (MK-0616-040)
Details : Enlicitide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 01, 2025
Details:
Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Enlicitide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2025
Lead Product(s) : Enlicitide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 18, 2025
Details:
Lithium Carbonate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Lithium Carbonate,Enlicitide
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2024
Lead Product(s) : Lithium Carbonate,Enlicitide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)
Details : Lithium Carbonate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 06, 2024
Details:
Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.
Lead Product(s): Enlicitide,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 16, 2024
Lead Product(s) : Enlicitide,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
Details : Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 16, 2024
Details:
Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Enlicitide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2024
Lead Product(s) : Enlicitide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)
Details : Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 24, 2024
Details:
Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Enlicitide,Digoxin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Celerion
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024
Lead Product(s) : Enlicitide,Digoxin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 19, 2024
Details:
Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatic Insufficiency.
Lead Product(s): Enlicitide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2024
Lead Product(s) : Enlicitide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
Details : Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatic Insufficiency.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 28, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
36
PharmaCompass offers a list of Enlicitide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Enlicitide manufacturer or Enlicitide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Enlicitide manufacturer or Enlicitide supplier.
A Enlicitide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Enlicitide, including repackagers and relabelers. The FDA regulates Enlicitide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Enlicitide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Enlicitide supplier is an individual or a company that provides Enlicitide active pharmaceutical ingredient (API) or Enlicitide finished formulations upon request. The Enlicitide suppliers may include Enlicitide API manufacturers, exporters, distributors and traders.
Enlicitide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Enlicitide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Enlicitide GMP manufacturer or Enlicitide GMP API supplier for your needs.
A Enlicitide CoA (Certificate of Analysis) is a formal document that attests to Enlicitide's compliance with Enlicitide specifications and serves as a tool for batch-level quality control.
Enlicitide CoA mostly includes findings from lab analyses of a specific batch. For each Enlicitide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Enlicitide may be tested according to a variety of international standards, such as European Pharmacopoeia (Enlicitide EP), Enlicitide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Enlicitide USP).
